

# CIM Securities, LLC

Member FINRA / SiPC

**CIM Securities** is conducting an 8% Accrued Dividend \$9 million Series A Convertible Participating Preferred Offering. If you would like to learn more about this investment opportunity, please feel free to contact me to set up a meeting with the senior management team of **Zoo Pharma Dynamics, Inc.** (the "Company").

## What is Zoo Pharma Dynamics

For the past 11 years, Zoo Pharma Dynamics ("ZPD" or "Company") and its predecessor operations have been conducting research and development to find solutions to fight against Chronic Wasting Disease ("CWD"), other zoonotic diseases and optimal nutritional supplements for hoofed animals.

[Investor Pitch Deck](#)

[Zoo Pharma Dynamics Website](#)

[Core Product Video](#)



## What is Chronic Wasting Disease

CWD, is the Prion Disease that causes a fatal, neurological illness occurring in North American cervids (members of the deer family), including white-tailed deer, mule deer, elk, and moose. Since its discovery in 1967, CWD has spread geographically and increased in prevalence locally. CWD is contagious and it can be transmitted freely within and among

cervid populations. No treatments or vaccines are currently available. CWD is of great concern to [wildlife managers](#), the state agency biologists or private sector biologists that manage wildlife resources. CWD has been detected in at least 23 states, two Canadian provinces in North America. CWD outbreaks are occurring in Europe and several other countries.

### Stopping Hunger

How Hunters Are Positioned to Address Food Insecurity in America. Each state has some variation on the [Hunters for the Hungry program](#). Recent survey data shows that hunters donate nearly 10 million pounds of game meat annually, which provides approximately [40 million healthy meal servings](#) that help battle food insecurity. [CWD is hampering](#) the hunter with the Good Samaritan practice of donating to those in need.

### Economic Impact of CWD

CWD is a serious disease that affects over 243,000 farmed cervids and is estimated to have a [\\$7.9 billion-dollar economic impact](#) annually in the US and Canada alone. The realized economic costs of CWD are considerable, and it is likely that the number of stakeholders financially affected by this disease and regulations meant to stem its spread will continue to grow rapidly on farmed and free-ranging Cervid's.

### ZPD Solutions

Zoo Pharma's products use patent-pending and trade secret-protected technology to produce the ingredient formulations to fight the prion disease, "CWD." The prion fighting ingredients in Cervid Prion Preventative, "CPP" are natural plant extracts combined with other ingredients to destroy the prion. ZPD believes the formulation can make an impact on this serious disease.

### FDA / Center Veterinary Medicine (CVM)

ZPD is in the new drug approval process with FDA under an INADE and ONADE file for our product CPP to fight the prion disease that causes CWD. We are projecting approval in late 2024 or early 2025. We are continuing to conduct field trials to enhance the formulations of CPP along with research on new products in the development stage.

### Product Valuation

ZPD hired an independent consulting firm, Brakke Consulting, that specializes in the animal healthcare industry to provide a monetary valuation on CPP, including a produced projection on one of ZPD's products that contains CPP. [Click Here to Read Valuation.](#)

Thank you for your time, I look forward to speaking with you.

Jack Myers  
VP, Investment Banking  
CIM Securities, LLC  
Member FINRA / SIPC

Phone: (619) 749-2460  
Mobile: (619) 249-5926

Email: [JackMyers@cimsecurities.com](mailto:JackMyers@cimsecurities.com)  
Website: [www.cimsecurities.com](http://www.cimsecurities.com)

*If you would like to Unsubscribe, Please Click Here: [UNSUBSCRIBE.](#)*

**Securities and Insurance Products are offered through registered representatives of CIM Securities, LLC (“CIM”) an independent registered broker-dealer. CIM is a Member of FINRA/SIPC. OSJ phone: [732-966-9244](tel:732-966-9244). Securities and Insurance Products: NOT FDIC INSURED - NOT Bank Deposits - NOT INSURED By Any Government Agency - NOT GUARANTEED BY ANY Financial Institution - May Lose Value.**

**The information presented has been obtained from sources we believe to be reliable; however, CIM Securities, LLC has not verified, and will not verify, any of the information contained herein, nor has CIM Securities LLC conducted any investigation regarding these matters and makes no warranty or representation whatsoever regarding the accuracy or completeness of the information provided. All potential buyers must take appropriate measures to verify all of the information set forth herein. Investments herein are illiquid, speculative, and there is a risk of total loss.**

**CONFIDENTIALITY NOTICE: The information contained in this e-mail communication and any attached documentation may be privileged, confidential, or otherwise protected from disclosure and is intended only for the use of the designated recipient(s). It is not intended for transmission to, or receipt by, any unauthorized person. The use, distribution, transmittal, or re-transmittal by an unintended recipient of this communication is strictly prohibited without our express approval in writing. If you are not the intended recipient of the e-mail, please delete it from your system without copying it and notify the above sender so that our e-mail address may be corrected.**

**ARCHIVING NOTICE: Recipients should be aware that all emails exchanged with the sender are automatically archived and subject to review at any time by duly authorized persons and may be produced to other parties, including public authorities, in compliance with applicable laws.**

**Under the terms of the CAN SPAM Act 2003, if you wish to alter your communications with Jack Myers at CIM Securities, LLC then you can either REPLY to this email and request Removal or you may click here on the [UNSUBSCRIBE](#) link below my signature block. If you do not reply to this email, we will assume you are satisfied with your email communications from us.**

**Past Performance is no guarantee of future results, investing in REG D private placements is extremely risky and one should consult with an investment professional before investing. Private Offerings are highly speculative securities, an investor could lose their entire principal investment and may be required to hold the securities for an indefinite period of time.**

**[PLACEMENT AGENT DISCLOSURE:](#)**

**This Disclosure Statement is being provided to you to describe the relationship among [Zoo Pharma Dynamics \(www.zoopharmadynamics.com\)](http://www.zoopharmadynamics.com) (the “Company”) and [CIM Securities, LLC](#) (“CIM”), relating to your investment in the Company private placement transaction (“Transaction”). CIM is a registered broker dealer member of [FINRA](#) and SIPC. The Company and CIM are not related parties.**

The Company and CIM have entered into an Engagement Letter Agreement (“Agreement”) under which CIM provides advisory services and solicits investor prospects of preferred shares (“Shares”) for the Company and the Company compensates CIM for referring investors to the Company. For each person or entity (including “You”, the “Investor”) that is solicited by CIM pursuant to the terms and conditions of the Agreement, who acquires or commits to acquire an interest in the Company, within a defined time period, as a result of such solicitation, Company shall pay, or cause to be paid, to CIM and any licensed Selling Agents it may be working with a fee of up to **Ten (10%) Percent** of gross transaction proceeds to the Company, in cash **Seven (7%) Percent of Placement Agent Common Stock Warrants** (“PA Warrants”) based on the number of Preferred Shares (“Shares”) purchased by the Investors with a seven (7) year term and cashless exercise provision exercisable at **\$1.50 per Share**. CIM has been contracted for and up approximately \$24,500 as a full Retainer Fee and Legal Reimbursement for this Capital Raise as well as for its Legal Counsel.

This compensation to CIM does not in any way affect the number of shares that would be issued to you in the event that you acquired such interest without the solicitation of CIM or any of its Selling Agents. These fees may cause a conflict between your interests and CIM’s. Registered Representatives of CIM and their family members may be or may become investors in this Transaction or any other Company issuance. This may also cause a conflict of interest in your investment. Registered Representatives of CIM and Selling Agents may be engaged to solicit other transactions at higher or lower compensation agreements, which may also be a conflict of interest to your solicitation for this investment. Please review the [Customer Relationship Summary \(CRS\) of CIM Securities](#).

Confidentiality Notice: This email, including any attachments, may include confidential and/or proprietary information. The reader is hereby notified that any unauthorized dissemination or copying of this email is prohibited. If you have received this email in error, please notify the sender immediately by replying to this message and delete this email. Do not use email to request, authorize or effect the purchase or sale of any security, to send fund transfer instructions, or to effect any other transactions relating to your account. In compliance with SEC and FINRA requirements, CIM Securities and its affiliates employ email monitoring software for the review of email messages. Under the terms of the SPAM Act 2003, if you wish to alter your communications with Jack Myers, Choice Investment Management and/or CIM Securities, LLC then you **MUST REPLY** to this email. **If you no longer want to receive these messages, simply click the Unsubscribe link above or REPLY to this email** and you will be unsubscribed from future communications for the email address this communication was sent, and it will be deleted from our database.

THE ATTACHED DOCUMENTS AND INTRO LETTER INCLUDED HEREIN ARE TO BE STRICTLY CONSIDERED "PRELIMINARY INFORMATION MATERIALS" AND DOES NOT CONSTITUTE ANY OFFER TO SELL OR SOLICITATION OF AN OFFER TO BUY ANY SECURITY MENTIONED HEREIN. AN OFFER CAN ONLY BE MADE BY AN APPROPRIATE SUBSCRIPTION AGREEMENT AND THE FULL PRIVATE PLACEMENT MEMORANDUM WHICH THESE DOCUMENTS ARE A PART OF UNDER A REG D 506(c) OFFERING AND ONLY IN STATES IN WHICH THE

OFFERING OF THE SECURITIES IS REGISTERED OR EXEMPT FROM REGISTRATION AND BY FINRA REGISTERED BROKER-DEALERS AUTHORIZED TO DO SO. EACH PRIVATE INVESTMENT TRANSACTION HAS ITS OWN INHERENT RISKS AND ONE SHOULD READ THE FULL MEMORANDUM / SUBSCRIPTION AGREEMENT IN AND CONSIDER ALL THE UNIQUE RISKS INVOLVED AND DO APPROPRIATE DUE DILIGENCE BEFORE INVESTING. ANY MENTION OF PAST PERFORMANCE ON ANY PAST TRANSACTIONS IS NO GUARANTEE OF FUTURE RESULTS. **THESE ARE HIGHLY SPECULATIVE AND ILLIQUID SECURITIES, WHICH INVOLVE A HIGH DEGREE OF RISK. ONLY THOSE INVESTORS WHO CAN HOLD THESE SECURITIES FOR AN INDEFINITE PERIOD OF TIME AND BEAR THE LOSS OF THEIR ENTIRE INVESTMENT SHOULD INVEST IN THESE SECURITIES.**

You should speak with your financial advisor, accountant, tax consultant and/or attorney when evaluating private placement offerings. The information you will review may contain forward-looking statements about investments which have not been reviewed by CIM Securities. You should not rely on these statements but should carefully evaluate the Materials in assessing any private investment opportunity, including the complete set of risk factors that are provided for your consideration. Articles or information from third-party sources may discuss CIM Securities or relate to information contained herein, but CIM does not approve and is not responsible for such content. Hyperlinks to third-party sites, or reproduction of third-party content, do not constitute an approval or endorsement by CIM of the linked or reproduced content. Risk statement: Keep in mind that strong investor interest is no indication of the merits of the investment.

**CAUTIONARY NOTICE RELATING TO FORWARD-LOOKING STATEMENTS:** These Preliminary Information Materials and/or Private Placement Memorandum contain "forward-looking statements" within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, including statements regarding, among other items, the Company's business strategies, continued growth in the Company's markets, projections and anticipated trends in the Company's business and the industry in which it operates. The words "believe," "expect," "anticipate," "intends," "forecast," "project" and similar expressions identify forward-looking statements. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties that are beyond the Company's control. the Company cautions that these statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements, including, among others, the following: reduced or lack of demand for the Company's Services, competitive pricing pressures, unexpected changes in the industry or economic environment and the level of expenses incurred in the Company's operations. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in these Materials and the documents incorporated herein by reference will, in fact, occur or prove to be accurate.